Literature DB >> 9234361

Can a cysteine challenge assay predict the in vivo behavior of 99mTc-labeled antibodies?

D J Hnatowich1, F Virzi, M Fogarasi, M Rusckowski, P Winnard.   

Abstract

Recent investigations have shown that transchelation to cysteine in a principal mode of in vivo instability of 99mTc-labeled antibodies. In this investigation, a cysteine challenge assay was used to measure the in vitro instability of 99mTc directly labeled to two IgG antibodies (B72.3 and C110) via two established direct labeling methods employing mercaptoethanol and stannous ion for antibody reduction and by a novel method using glutathione for this purpose. For both antibodies, the greatest instability to cysteine occurred with stannous ion reduction. The stability of glutathione-reduced B72.3 was indistinguishable from mercaptoethanol-reduced B72.3 whereas glutathione-reduced C110 showed stability roughly intermediate between that of the other reducing agents for this antibody. Results obtained in normal mice were in the direction predicted by the assay: for both antibodies, urinary clearance of 99mTc was fastest in mice receiving antibodies labeled via stannous ion reduction, presumably because of the increased transchelation of label to cysteine in vivo. Urinary clearance was slower and identical in mice receiving B72.3 labeled via glutathione or mercaptoethanol whereas clearance in the case of glutathione-reduced C110 was intermediate between that of the other two reducing agents. At both time points, higher radioactivity levels were observed in kidneys and lower levels in blood and most other tissues for both antibodies in the case of stannous ion reduction as expected for the label of greatest instability. In the B72.3 case, with only one exception, tissue and blood levels following administration of glutathione-reduced antibody were indistinguishable from that following administration of mercaptoethanol-reduced antibody. In the C110 case, significant differences in activity levels were observed in several tissues between glutathione- and mercaptoethanol-reduced antibodies. In conclusion, the relative in vivo behaviour of 99mTc when administered to mice while labeled to two IgG antibodies were successfully predicted based on the results of an in vitro cysteine challenge assay.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 9234361     DOI: 10.1016/0969-8051(94)90175-9

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  7 in total

1.  Direct technetium-99m labeling of anti-hepatoma monoclonal antibody fragment:a radioimmunoconjugate for hepatocellular carcinoma imaging.

Authors:  Hui-Jie Bian; Zhi-Nan Chen; Jing-Lan Deng
Journal:  World J Gastroenterol       Date:  2000-06       Impact factor: 5.742

2.  Site-specific conjugation and labelling of prostate antibody 7E11C5.3 (CYT-351) with technetium-99m.

Authors:  M A Stalteri; S J Mather; B A Belinka; D J Coughlin; V U Chengazi; K E Britton
Journal:  Eur J Nucl Med       Date:  1997-06

3.  Technetium-99m labelling of the anti-tumour antibody PR1A3 by photoactivation.

Authors:  M A Stalteri; S J Mather
Journal:  Eur J Nucl Med       Date:  1996-02

4.  Characterization of 99mTc-labeled cytokine ligands for inflammation imaging via TNF and IL-1 pathways.

Authors:  Zhonglin Liu; Leonie Wyffels; Christy Barber; Li Wan; Hua Xu; Mizhou M Hui; Lars R Furenlid; James M Woolfenden
Journal:  Nucl Med Biol       Date:  2012-06-28       Impact factor: 2.408

5.  99mTc Stearyl 6-(benzylidenehydrazinyl) nicotinamide Liposomes as Tumor Permeability Evaluation Tracer.

Authors:  Mirel Cabrera; Nicole Lecot; Marcelo Fernández; J P Gambini; Williams Porcal; Pablo Cabral
Journal:  AAPS PharmSciTech       Date:  2021-03-24       Impact factor: 3.246

6.  Feasibility of imaging of epidermal growth factor receptor expression with ZEGFR:2377 affibody molecule labeled with 99mTc using a peptide-based cysteine-containing chelator.

Authors:  Ken G Andersson; Maryam Oroujeni; Javad Garousi; Bogdan Mitran; Stefan Ståhl; Anna Orlova; John Löfblom; Vladimir Tolmachev
Journal:  Int J Oncol       Date:  2016-10-05       Impact factor: 5.650

7.  Influence of composition of cysteine-containing peptide-based chelators on biodistribution of 99mTc-labeled anti-EGFR affibody molecules.

Authors:  Maryam Oroujeni; Ken G Andersson; Xenia Steinhardt; Mohamed Altai; Anna Orlova; Bogdan Mitran; Anzhelika Vorobyeva; Javad Garousi; Vladimir Tolmachev; John Löfblom
Journal:  Amino Acids       Date:  2018-05-04       Impact factor: 3.520

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.